CR20120485A - Procedimientos para la producción de complejos de ciclodextrina para formular inhibidores del proteasoma peptídico - Google Patents

Procedimientos para la producción de complejos de ciclodextrina para formular inhibidores del proteasoma peptídico

Info

Publication number
CR20120485A
CR20120485A CR20120485A CR20120485A CR20120485A CR 20120485 A CR20120485 A CR 20120485A CR 20120485 A CR20120485 A CR 20120485A CR 20120485 A CR20120485 A CR 20120485A CR 20120485 A CR20120485 A CR 20120485A
Authority
CR
Costa Rica
Prior art keywords
inhibitors
formulate
procedures
production
peptide proteasome
Prior art date
Application number
CR20120485A
Other languages
English (en)
Inventor
Evan Lewis
Peter Shwonek
Sean Dalziel
Mouhannad Jumaa
Original Assignee
Onyx Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49549072&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20120485(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Onyx Therapeutics Inc filed Critical Onyx Therapeutics Inc
Publication of CR20120485A publication Critical patent/CR20120485A/es

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

La presente divulgación proporciona procedimientos para formular composiciones que comprenden uno o más inhibidores del proteasoma peptídico y una ciclodextrina, en particular una ciclodextrina sustituida.
CR20120485A 2012-05-08 2012-09-26 Procedimientos para la producción de complejos de ciclodextrina para formular inhibidores del proteasoma peptídico CR20120485A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261644122P 2012-05-08 2012-05-08

Publications (1)

Publication Number Publication Date
CR20120485A true CR20120485A (es) 2013-12-18

Family

ID=49549072

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20120485A CR20120485A (es) 2012-05-08 2012-09-26 Procedimientos para la producción de complejos de ciclodextrina para formular inhibidores del proteasoma peptídico

Country Status (21)

Country Link
US (2) US20130303482A1 (es)
JP (1) JP2015516416A (es)
KR (1) KR20150007361A (es)
CN (1) CN103781490A (es)
AR (2) AR087863A1 (es)
AU (1) AU2012238318B2 (es)
BR (1) BR112012028726B1 (es)
CA (1) CA2793894A1 (es)
CO (1) CO6571868A2 (es)
CR (1) CR20120485A (es)
CU (1) CU20120159A7 (es)
DO (1) DOP2012000252A (es)
EA (1) EA201201519A1 (es)
EC (1) ECSP12012167A (es)
MA (1) MA35238B1 (es)
MX (1) MX2012010891A (es)
MY (2) MY165002A (es)
SG (1) SG194417A1 (es)
TW (1) TWI603737B (es)
WO (1) WO2013169282A1 (es)
ZA (1) ZA201207384B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
CN104271605B (zh) 2012-02-15 2017-07-25 锡德克斯药物公司 环糊精衍生物的制造方法
KR20150131276A (ko) 2013-03-14 2015-11-24 오닉스 세라퓨틱스, 인크. 디펩타이드 및 트리펩타이드 에폭시 케톤 프로테이스 억제제
AR095426A1 (es) 2013-03-14 2015-10-14 Onyx Therapeutics Inc Inhibidores tripeptídicos de la epoxicetona proteasa
GB201312737D0 (en) 2013-07-17 2013-08-28 Univ Greenwich Cyclodextrin
CA2918530C (en) 2013-07-19 2023-10-03 Onyx Therapeutics, Inc. Peptide epoxyketone proteasome inhibitors in combination with pim kinase inhibitors for treatment of cancers
CN104945470B (zh) * 2014-03-30 2020-08-11 浙江大学 杂环构建的三肽环氧酮类化合物及制备和应用
CN103936828A (zh) * 2014-05-12 2014-07-23 苏州科耐尔医药科技有限公司 卡非佐米中间体及卡非佐米的制备方法
CN105919972A (zh) * 2015-12-18 2016-09-07 重庆两江药物研发中心有限公司 一种包载卡非佐米的纳米粒制剂及其制备方法
TWI759301B (zh) 2016-05-24 2022-04-01 美商安美基公司 聚乙二醇化卡非佐米化合物
WO2018027021A1 (en) 2016-08-05 2018-02-08 Amgen Inc. Synthesis of (s)-2-amino-4-methyl-1-((r)-2-methyloxirane-2-yl)-pentan-1-one and pharmaceutically acceptable salts thereof
WO2018038687A1 (en) 2016-08-22 2018-03-01 Mustafa Nevzat Ilaç Sanayii A.Ş. Pharmaceutical formulations comprising a bortezomib-cyclodextrin complex
US20180282260A1 (en) * 2017-03-31 2018-10-04 Valent Biosciences Llc 1-aminocyclopropane-1-carboxylic acid polymorphs
US10975121B2 (en) 2017-06-24 2021-04-13 Cytogel Pharma, Llc Analgesic mu-opioid receptor binding peptide pharmaceutical formulations and uses thereof
MX2020004936A (es) 2017-11-16 2020-08-27 Amgen Inc Composiciones estables de compuestos de carfilzomib pegilado.
CN111683654A (zh) * 2017-11-30 2020-09-18 细胞凝胶制药有限责任公司 新型镇痛药物制剂及其用途
EP4168148A1 (en) * 2020-06-19 2023-04-26 Amgen Inc. Methods of measuring carfilzomib
US11246874B1 (en) 2021-04-20 2022-02-15 Oxygen Biotech LLC Treatment of COVID-19

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1819353B1 (en) * 2004-12-07 2011-02-23 Proteolix, Inc. Composition for proteasome inhibition
US8716322B2 (en) * 2005-11-09 2014-05-06 Onyx Therapeutics, Inc. Compounds for enzyme inhibition
ME02462B (me) * 2007-10-04 2017-02-20 Onyx Therapeutics Inc Inhibitori kristalne peptid epoksi keton proteaze i sinteza aminokiselinskih keto- epoksida

Also Published As

Publication number Publication date
BR112012028726A2 (pt) 2016-07-19
AU2012238318A1 (en) 2013-11-28
AU2012238318B2 (en) 2014-02-13
AR127861A2 (es) 2024-03-06
US20130303465A1 (en) 2013-11-14
MX2012010891A (es) 2014-03-05
BR112012028726B1 (pt) 2021-07-13
MA35238B1 (fr) 2014-07-03
WO2013169282A1 (en) 2013-11-14
US20130303482A1 (en) 2013-11-14
CA2793894A1 (en) 2013-11-08
CO6571868A2 (es) 2012-11-30
TW201345543A (zh) 2013-11-16
EA201201519A1 (ru) 2013-11-29
CN103781490A (zh) 2014-05-07
DOP2012000252A (es) 2013-12-31
KR20150007361A (ko) 2015-01-21
MY196510A (en) 2023-04-18
ZA201207384B (en) 2018-12-19
CU20120159A7 (es) 2014-03-26
JP2015516416A (ja) 2015-06-11
AR087863A1 (es) 2014-04-23
MY165002A (en) 2018-02-28
NZ602490A (en) 2016-03-31
SG194417A1 (en) 2013-12-30
TWI603737B (zh) 2017-11-01
ECSP12012167A (es) 2013-02-28

Similar Documents

Publication Publication Date Title
CR20120485A (es) Procedimientos para la producción de complejos de ciclodextrina para formular inhibidores del proteasoma peptídico
UY34804A (es) Inhibidores del nampt
CO7151512A2 (es) Inhibidores del nampt
AR093645A1 (es) Una formulacion estabilizada de pemetrexed
UA114655C2 (uk) Піридин-2-аміди, придатні як агоністи канабіноїдного рецептора 2
MY167947A (en) Absorbent article
CO7160079A2 (es) Composiciones líquidas de racecadotrillo
UA116239C2 (uk) Нові похідні піридину
TWD160618S (zh) 硏磨件
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.
CO7020915A2 (es) Inhibidores de iap
DOP2017000058A (es) Derivados de tetrahidroquinolina como inhibidores del bromodominio
MY158023A (en) Curable resin composition and semiconductor device using same
BR112014016803A2 (pt) amidas macrocíclicas como inibidoras de protease
UY34829A (es) Nueva dosificación y formulación
UA112760C2 (uk) Теобромін у комбінації з гвайфенезином для лікування кашлю
TR201903918T4 (tr) Bir dağıtım ajanı içeren bileşimler ve bunların hazırlanması.
MX2015006986A (es) Solucion de trombina y metodos de uso de esta.
DK2916914T3 (da) N-acetyl-L-cystein til anvendelse i in vitro befrugtning
MX2015016766A (es) Nuevos derivados de tetrazolona.
EP2811999A4 (en) NOVEL CYSTEINE PROTEASE INHIBITORS AND USES THEREOF
BR112013025764A2 (pt) dispositivo impulsionador
BR112013027391A2 (pt) formulação farmacêutica, frasco e kit
EP3054947A4 (en) Cathepsin cysteine protease inhibitors
BR112013027390A2 (pt) formulação farmacêutica